Karyopharm Therapeutics (KPTI) Financials: History & Chart

Karyopharm Therapeutics Inc.(KPTI)

Biotechnology · Newton, MA

$0.65-0.02 (-3.07%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Newton, MA

228 employees

www.karyopharm.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Richard A. Paulson

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	146.62M	33.43M	35.07M	34.08M	44.04M	37.93M	30.02M	30.54M	38.78M
Cost of Goods Sold	6.04M	1.08M	1.36M	1.48M	2.11M	1.05M	1.30M	1.33M	1.30M
Gross Profit	140.58M	32.35M	33.71M	32.59M	41.93M	36.88M	28.71M	29.21M	37.48M
Gross Profit Margin	95.9%	96.8%	96.1%	95.6%	95.2%	97.2%	95.7%	95.6%	96.6%
Total Operating Expenses	222.93M	54.87M	60.47M	50.44M	57.15M	61.27M	61.97M	60.49M	63.77M
Research & Development	121.94M	29.95M	33.78M	27.67M	30.54M	32.79M	34.62M	33.30M	36.13M
Selling, General & Administrative	101.98M	25.92M	26.68M	22.77M	26.61M	28.48M	27.35M	27.19M	27.63M
Operating Income (EBIT)	-82.35M	-22.53M	-26.76M	-17.84M	-15.22M	-24.39M	-33.26M	-31.28M	-26.28M
Operating Margin	-56.2%	-67.4%	-76.3%	-52.4%	-34.6%	-64.3%	-110.8%	-102.4%	-67.8%
Income Before Tax (EBT)	-224.77M	-67.02M	-22.39M	-102.27M	-33.09M	-37.21M	-23.43M	-30.89M	-32.04M
Interest Income	2.39M	722K	511K	607K	553K	613K	1.00M	1.48M	1.83M
Interest Expense	49.32M	13.14M	12.55M	12.62M	11.01M	11.23M	10.99M	11.20M	11.38M
Other Income/Expense	-142.42M	-44.50M	4.37M	-84.42M	-17.87M	-12.82M	9.83M	392K	-5.76M
Net Income	-224.74M	-67.02M	-22.39M	-102.20M	-33.13M	-37.25M	-23.46M	-30.78M	-32.07M
Income Tax Expense	-32K	0.00	1K	-67K	34K	40K	36K	-109K	28K
Net Profit Margin	-153.3%	-200.5%	-63.9%	-299.9%	-75.2%	-98.2%	-78.2%	-100.8%	-82.7%
EBITDA	N/A	N/A	-26.75M	-17.82M	-15.14M	-24.31M	-33.18M	-31.20M	-26.20M
EBITDA Margin	N/A	N/A	-76.3%	-52.3%	-34.4%	-64.1%	-110.5%	-102.2%	-67.6%
Depreciation & Amortization	106K	-3K	12K	19K	78K	78K	78K	81K	83K
EPS Basic	-22.32	-2.32	-1.02	-15.16	-3.82	-4.32	-2.77	N/A	-3.85
EPS Diluted	-13.07	-2.32	-1.24	-5.69	-3.82	-4.32	-2.77	N/A	-3.85
Weighted Average Basic Shares	28.94M	28.94M	22.01M	6.74M	8.67M	8.62M	8.47M	8.39M	8.33M
Weighted Average Diluted Shares	28.94M	28.94M	24.71M	18.21M	8.67M	8.62M	8.47M	8.39M	8.33M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	146.07M	145.24M	146.03M	157.07M	209.82M	108.08M	40.89M	30.34M
Cost of Goods Sold	5.95M	6.01M	4.94M	5.21M	3.40M	2.71M	2.41M	161.37M
Gross Profit	140.12M	139.23M	141.09M	151.86M	206.42M	105.38M	38.49M	-131.04M
Gross Profit Margin	95.9%	95.9%	96.6%	96.7%	98.4%	97.5%	94.1%	-431.9%
Total Operating Expenses	230.82M	258.67M	270.63M	294.06M	304.69M	277.23M	227.76M	210.22M
Research & Development	125.62M	143.23M	138.75M	148.66M	160.84M	150.81M	122.34M	161.37M
Selling, General & Administrative	105.21M	115.44M	131.88M	145.40M	143.85M	126.42M	105.42M	48.85M
Operating Income (EBIT)	-90.71M	-119.44M	-129.54M	-142.20M	-98.27M	-171.85M	-189.28M	-179.88M
Operating Margin	-62.1%	-82.2%	-88.7%	-90.5%	-46.8%	-159.0%	-462.9%	-593.0%
Income Before Tax (EBT)	-196.00M	-76.36M	-142.78M	-164.92M	-123.82M	-195.96M	-199.55M	-178.38M
Interest Income	2.77M	7.40M	10.94M	2.36M	582K	2.82M	5.42M	4.03M
Interest Expense	45.85M	37.42M	23.82M	25.00M	26.05M	27.14M	15.65M	2.49M
Other Income/Expense	-105.29M	43.08M	-13.24M	-22.72M	-25.55M	-24.11M	-10.28M	1.50M
Net Income	-196.04M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M	-199.59M	-178.41M
Income Tax Expense	43K	57K	323K	369K	268K	309K	40K	26K
Net Profit Margin	-134.2%	-52.6%	-98.0%	-105.2%	-59.1%	-181.6%	-488.1%	-588.1%
EBITDA	-90.41M	-119.10M	-129.01M	-141.58M	-97.48M	-170.88M	-188.30M	-179.15M
EBITDA Margin	-61.9%	-82.0%	-88.3%	-90.1%	-46.5%	-158.1%	-460.5%	-590.5%
Depreciation & Amortization	296K	340K	530K	621K	789K	972K	974K	735K
EPS Basic	-17.93	-9.41	-18.79	-30.28	-24.75	-40.87	-48.32	-47.11
EPS Diluted	-17.93	-9.41	-18.79	-30.28	-24.75	-40.87	-48.32	-47.11
Weighted Average Basic Shares	10.94M	8.12M	7.61M	5.46M	5.01M	4.80M	4.13M	3.79M
Weighted Average Diluted Shares	10.94M	8.12M	7.61M	5.46M	5.01M	4.80M	4.13M	3.79M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.